Pharma Journalist -

Novelion Therapeutics Inc. announced that its subsidiary, Aegerion Pharmaceuticals has entered into an exclusive licensing agreement with Recordati Rare Diseases Inc. for the…
Read More...

Taiho Pharmaceutical and Cullinan Oncology announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered…
Read More...

Moderna, Inc., announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in…
Read More...

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD)…
Read More...

The pivotal Phase 3 trial of isatuximab in patients with relapsed/refractory multiple myeloma met the primary endpoint of prolonging progression free survival in patients treated with…
Read More...

Building on last year’s success SMi Group are proud to present the 4th Pre-filled Syringes West Coast 2019 Conference and exhibition in CA, USA. Conference Overview: Pre-Filled…
Read More...

Trevi Therapeutics announced that it had entered into exclusive license agreements with Rutgers, The State University of New Jersey and MentiNova, Inc. for intellectual property and…
Read More...

IQVIA announced the launch of IQVIA Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies. This solutions…
Read More...

Hear from Sanofi as they will be presenting the Keynote Address: Overcoming the challenges in development of injectable protein formulations on day one by Vasco Filipe, Senior research…
Read More...

Verseon’s phase 1 trial in healthy volunteers, which started dosing last week, could lead to a new treatment standard for millions of cardiac patients who would benefit from long-term…
Read More...